Opendata, web and dolomites


Liquid Foam Therapy (LIFT) for Acute Respiratory Distress Syndrome (ARDS)

Total Cost €


EC-Contrib. €






 LIFT project word cloud

Explore the words cloud of the LIFT project. It provides you a very rough idea of what is the project "LIFT" about.

expand    intensive    advocate    care    span    meanwhile    broadly    255    homogeneously    replacement    mortality    printed    disease    airway    clinical    vitro    patent    3d    rates    gravity    larger    treatment    sepsis    fail    surfactant    drains    animal    aerosols    administration    therapeutic    foam    pending    ards    shift    inhalation    demonstrated    fluoroscopy    vivo    microfabricated    experiments    srt    distress    caused    people    obstructive    patients    newborn    pools    nebulizers    distributes    133    babies    biomedical    copd    age    medicine    chest    pig    ex    groups    endotracheal    chronic    forces    paradigm    team    children    idiopathic    liquid    small    anesthetized    hurdles    1ml    bridges    injury    leveraged    poc    inadequate    optimize    device    therapies    procedure    formulation    pneumonia    hr    doses    ipf    lift    business    engineering    therapy    tension    feasibility    adults    inflammatory    treat    coating    abundance    syndrome    run    leaving    lt    inner    acute    lungs    expertise    cell    extend    reduces    brings    head    100ml    stem    depletion    excised    40    surface    carrier    construct    respiratory    life    neonates    overcome    instillations    lay    drowning    annually    regions    pulmonary    saving    untreated    fibrosis    lung    models   

Project "LIFT" data sheet

The following table provides information about the project.


Organization address
city: HAIFA
postcode: 32000

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Acute Respiratory Distress Syndrome (ARDS) is an inflammatory lung condition caused e.g. by sepsis, pneumonia and head or chest injury, affecting annually 133,000 people in Europe and 255,000 in the US. ARDS is characterized by the depletion of the lungs’ inner liquid coating (pulmonary surfactant), which reduces surface tension forces and allows the lungs to expand. Patients span across all age groups and lay anesthetized in the intensive care unit with mortality rates at 40%. Although surfactant replacement therapy (SRT) is a life-saving procedure in newborn neonates, current administration methods to treat adults and even children remain inadequate. Endotracheal surfactant liquid instillations used in babies fail in larger lungs: liquid drains into pools, drowning these lung regions while leaving others untreated. Meanwhile, inhalation aerosols can only deliver small doses (<1ml/hr for nebulizers), far from the required ~100ml of surfactant. To overcome such hurdles, we advocate using liquid foam as a surfactant carrier to the lungs, i.e. LIquid Foam Therapy (LIFT). Foam is weakly affected by gravity, distributes homogeneously within lungs and in abundance. LIFT brings a paradigm shift in SRT, and more broadly, in the field of therapeutic pulmonary delivery. Our team bridges expertise in clinical ARDS treatment in neonates, pulmonary medicine, biomedical engineering and business. Together, we have demonstrated the feasibility of our patent pending technology, both in vitro in 3D printed and microfabricated airway models, and ex vivo in excised pig lungs using fluoroscopy. In this PoC, we will optimize the foam formulation, design and construct a delivery device, and run pre-clinical in vivo animal experiments. LIFT has the potential to extend far beyond ARDS treatment and be leveraged for other lung therapies, such as stem cell delivery directly to the lungs to treat Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIFT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIFT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More